The impact of PM2.5, PM10 and NO2 on Covid-19 severity in a sample of patients with multiple sclerosis: A case-control study

Marta Ponzano a,*, Irene Schiavetti a, Roberto Bergamaschi b, Enrico Pisoni c, Andrea Bellavia d, Giulia Mallucci b, Luca Carmicisiano e, Matilde Inglese a,f, Cinzia Cordioli a, Girolama Alessandra Marfia h, Eleonora Cocco i, Paolo Immovilli j, Ilaria Pesci k, Cinzia Scandellari l, Paola Cavalla m, Marta Radaelli n, Marika Vianello o, Francesca Vitetta p, Sara Montepietra q, Maria Pia Amato r, Cristina Fioretti s, Massimo Filippi t, u,v,w,x, Arianna Sartori y, Francesca Caleri z, Marinella Clerico a,h, Antonio Gallo a,b, Antonella Conte ac, Raffaella Clerici ad, Giovanna De Luca ae, Filippo Martinelli Boneschi af, Roberto Cantello ag, Massimiliano Calabrese ah, Carla Tortorella ai, Marco Rovaris aj, Elena Pinuccia Verrengia ak, Francesco Patti al, Vincenzo Brescia Morra am, Marco Salvetti an,ao, Maria Pia Sormani as,af, MuSC-19 Study Group

a Department of Health Sciences, Section of Biostatistics, University of Genoa, Genoa, Italy
b Multiple Sclerosis Research Center, IRCCS Mondino Foundation, Pavia, Italy
c European Commission, Joint Research Centre (JRC), Ispra, Italy
d Department of Environmental Health, Harvard T.H. Chan School of Public Health, Boston, MA, USA
e Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DINO GME), University of Genoa, Genoa, Italy
f IRCCS Ospedale Policlinico San Martino, Genoa, Italy

Multiple Sclerosis Center, ASST Spedali Civili di Brescia, Montichari, Italy

Department of Systems Medicine, Multiple Sclerosis Clinical and Research Unit, Tor Vergata University, Rome, Italy

Multiple Sclerosis Center, Ospedale Binagli, Cagliari, Italy

Multiple Sclerosis Center of Toscana, Livorno, Italy

Department of Neurology, MS Center, F. Tappeiner Hospital, Merano, Italy

European Commission, Joint Research Centre (JRC), Ispra, Italy

Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DINO GME), University of Genoa, Genoa, Italy

Multiple Sclerosis Center, ASST Spedali Civili di Brescia, Montichari, Italy

Department of Systems Medicine, Multiple Sclerosis Clinical and Research Unit, Tor Vergata University, Rome, Italy

Multiple Sclerosis Center, Ospedale Guglielmo da Saliceto, Piacenza, Italy

Multiple Sclerosis Center, UO Neurology, Fidenza, Fidenza, Italy

IRCCS Institute of Neurological Sciences, UOSI Multiple Sclerosis Rehabilitation, Bologna, Italy

MS Center, Department of Neurosurgery, City of Health and Science University Hospital of Turin, Turin, Italy

Department of Neurology and Multiple Sclerosis Center, ASST "Papa Giovanni XXIII", Bergamo, Italy

Unit of Neurology, Ca' Foscari University, Venice, Italy

Neurology Unit, Azienda Ospedaliero-Universitaria di Modena, Modena, Italy

Neurology Unit, Neuroraptor and Rehabilitation Department, AUSL-IRCCS of Reggio Emilia, Reggio Emilia, Italy

IRCCS Don Carlo Gnocchi Foundation, Florence, Italy

Multiple Sclerosis Center of Toscana, Livorno, Italy

Neurology Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy

Neuropsychiatry Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy

Neuroimaging Research Unit, Division of Neuroscience, IRCCS San Raffaele Scientific Institute, Milan, Italy

Vita-Salute San Raffaele University, Milan, Italy

Clinical Unit of Neurology, Department of Medicine, Surgery and Health Sciences, ASUGI, University of Trieste, Trieste, Italy

Department of Neurology, MS Center, F. Tappeiner Hospital, Merano, Italy

Clinica Neurologica, Ospedale S. Maria della Misericordia, Udine, Italy

Clinical Unit of Neurology, Department of Medicine, Surgery and Health Sciences, ASUGI, University of Trieste, Trieste, Italy

Department of Neurology, MS Center, F. Tappeiner Hospital, Merano, Italy

Neurology Unit and MS Centre, Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy

Movement Disorders Centre, Neurology Unit, Department of Translational Medicine, University of Piemonte Orientale, Novara, Italy

Department of Neurosciences, Biomedicine and Movement, The Multiple Sclerosis Center of the University Hospital of Verona, Verona, Italy

* Corresponding author.
E-mail addresses: ponzano.marta@gmail.com (M. Ponzano),

https://doi.org/10.1016/j.msard.2022.104243

Received 28 July 2022; Received in revised form 19 September 2022; Accepted 14 October 2022

Available online 20 October 2022

2211-0348/© 2022 Elsevier B.V. All rights reserved.
1. Introduction

Many studies have pointed out that air pollution may play a role in the severity of SARS-CoV-2 infections, leading to higher risk of common Covid-19 complications (Zang et al., 2022; Bourdrel et al., 2021). Pneumonia is the most common complication in severe Covid-19 patients (Williams et al., 2022) and presence of this condition is sufficient to differentiate Covid-19 cases between mild and moderate or severe (World Health Organization, 2021). Air pollutants have also been associated to the occurrence and development of autoimmune diseases including Multiple Sclerosis (MS) (Zhao et al., 2019). In particular, higher pollutants concentrations have been identified as possible risk factors for MS onset and relapses (Bergamaschi et al., 2021; Tateo et al., 2019; Noorimotlagh et al., 2021). However, to the best of our knowledge, only one study explored the impact of air pollution on Covid-19 severity among patients with MS (Bergamaschi et al., 2022). This study revealed that higher concentrations of PM2.5 increase the risk of severe Covid-19 course among patients with MS, but there were some limitations. Firstly, PM2.5 long-term exposure was measured in correspondence to the patient-reported place of infection to Covid-19 even if they may have spent more time somewhere else in the more recent years. Secondly, it only focused on PM2.5 exposure without evaluating several pollutants simultaneously. Thus, our aim is to explore the association between air pollution and Covid-19 severity among MS patients with MS evaluating other pollutants at the same time (i.e. PM2.5, PM10 and NO2) and based on more precise information on the geographical area of exposure. Addressing and thoroughly evaluating this association among MS patients will provide critical information for identifying the effective role of the main air pollutants in worsening the course of Covid-19 infection. Since Covid-19 infection may carry additional reasons for concern among vulnerable individuals such as MS patients, increasing the knowledge of risk factors for severe outcomes within this specific group of patients can surely help to better protect them.

2. Methods

2.1. Study population

We designed a case-control study on MS patients living in Italy who got infected with Covid-19 differentiating cases of severe Covid-19 and controls based on the occurrence of documented pneumonia. All the data were retrieved from the MuS-C19 platform, an Italian web-based platform containing clinician-reported data on MS patients with Covid-19. Information on data sharing agreement and ethical committee approval as well as details on the data stored in the platform have been already reported (Sormanii et al., 2021). We excluded patients with suspected Covid-19 infections not confirmed by a positive Covid-19 test and those who got infected after having received at least one dose of Covid-19 vaccination in order to avoid bias. On 28 January 2022, data of 205 patients with Covid-19 related pneumonia were collected from the platform. To calculate the required number of controls, we conducted a sample size calculation fixing the odds ratio of severe Covid-19 to 1.79 based on the data of our pilot study (Bergamaschi et al., 2022) and alpha level to 0.05. To achieve a power of 0.90, two controls per case were required and thus 410 controls were randomly selected among patients without pneumonia.

2.2. Outcome assessment

A specific section of the platform was dedicated to radiological data, including information on the presence of documented pneumonia. This data were already available at the beginning of the study since clinicians had already completed this section.

2.3. Exposure assessment

To retrieve a precise information on the geographical area of exposure, the 615 eligible patients were contacted by investigators of their MS center and were asked the following question (in their mother tongue): “Where did you spend most of the active day (excluding
sleeping hours) in the last five years?”. In case of severe health conditions preventing the patient to reply to our question or in case of patient death, the caregiver was contacted instead of the patient. A new section of the Musc-19 platform was created, where the investigators could insert the zip codes of the geographical area provided by the patients. When this information was missing, the address of the MS center was used as a proxy in sensitivity analysis. Air quality was assessed as 2018 annual average particulate matter (PM2.5 and PM10) and Nitrogen Dioxide (NO2) ground-level concentrations derived from air quality model results as provided by the ‘Copernicus Atmospheric Monitoring Service’ (CAMS). In particular, the ‘reanalysis’ product (the most accurate in the CAMS ones, created through assimilation of modeling results and observations at ground-level), has been used. Concentrations were referred to 2018 since we evaluated long-term exposure related to the last five years (2018–2022) and ‘Copernicus Atmospheric Monitoring Service’ most recent available data (in terms of reanalysis) were available indeed at 2018 (Wagner et al., 2021).

2.4. Statistical analyses

Descriptive characteristics of the study population were presented as mean with standard deviation, median with interquartile range or absolute frequency and percentage, depending on the nature of the variables. Characteristics of cases and controls were compared performing Chi-squared test and T-test as appropriate.

The association between each pollutant and Covid-19 pneumonia was investigated using univariable logistic regression models as well as multivariable models adjusted for potential confounders selected a priori (age, sex, BMI, comorbidities, EDSS, MS type, disease duration and treatments). Correlations between pollutants concentrations were calculated using Pearson correlation coefficients.

We next evaluated the joint exposure to the three pollutants as an environmental mixture. Weighted quantile sum (WQS) logistic regression was used to create a pollution index based on PM2.5, PM10 and NO2 concentrations, to study associations of the index with the risk of pneumonia, and to identify the individual contribution of each pollutant within the mixture (Carrico et al., 2015; Czarnota et al., 2015). For WQS modeling, we categorized each exposure into terciles and used the entire sample for weights estimation, generating 300 bootstrap samples to evaluate the positive mixture index (Czarnota et al., 2015; Renzetti et al., 2021). Finally, to confirm the variable selection from WQS, the pollutants mixture was also evaluated using Least Absolute Shrinkage and Selection Operator (LASSO) penalized regression analysis, determining the optimal value of the penalty parameter using 10-fold cross validation (Tibshirani, 1996). Both the WQS and Lasso models were adjusted for the same set of confounders included in the multivariable logistic regression models. All statistical analyses were performed using Stata version 16.0 (Stata Corporation, College Station, TX, USA) and R version 3.6.0. All tests were two-sided and P-values < 0.05 were conventionally regarded to as statistically significant.

3. Results

Of the 615 eligible patients, 491 patients (80%) provided detailed place of exposure and were thus included in the principal analysis. For the remaining 124 patients, the zip code of their referred MS center was used as a proxy for the exposure and they were only included in the sensitivity analysis (Fig. 1). Average observed concentrations of PM2.5, PM10 and NO2 are shown for each province in Fig. 2, together with the observed proportion of cases. Pneumonia was reported as a complication of Covid-19 for 169 patients (34%) (Table 1). Average exposures to pollutants concentrations were higher in cases compared to patients without pneumonia (PM2.5: \( p = 0.020 \); PM10: \( p = 0.092 \); NO2: \( p = 0.009 \)). Median age was 46 years (IQR = 36–55) but MS patients with pneumonia were significantly older than the ones without pneumonia (\( p < 0.001 \)). MS patients with pneumonia had a worse profile in terms of MS course and more frequently reported comorbidities compared to controls. At the time of Covid-19 infection, 414 patients (84%) were on
disease modifying treatment; Ocrelizumab or Rituximab were more commonly used among cases (23% vs 11%). Results remained consistent in the sensitivity analysis (Supplementary Table 1).

Univariable and multivariable analyses evaluating factors associated with the odds of severe Covid-19 course are reported in Table 2. The results confirmed previous findings (Bergamaschi et al., 2022; Schiavetti et al., 2022) indicating higher PM2.5 concentrations, older age, higher BMI, presence of comorbidities, and anti-CD20 treatment as risk factors and identifying Interferon therapy as a protective factor. Concerning the other pollutants under study, higher concentrations of PM10 and NO2 were significantly associated with increased odds of developing pneumonia (PM10: 2nd vs 1st tercile OR(95% CI)=1.83
PM2.5 (34%), suggesting that these pollutants are the most important components of the mixture (Fig. 4). Consistently, Lasso method set PM10 coefficient to zero and selected PM2.5 and NO2 as important variables, either in the principal analysis or in the sensitivity analysis.

4. Discussion

In this study, long-term exposure to high concentrations of PM2.5 were found to increase the odds of Covid-19 pneumonia in a sample of patients with MS, confirming results from a previous study carried out on MS patients (Bergamaschi et al., 2022). Additionally, also PM10 and NO2 were found to be associated with increased odds of developing a severe Covid-19 course supporting the findings of other studies carried out on the general population (Zang et al., 2022; Karimi et al., 2022). Based on our results, we could thus infer that higher exposure to PM2.5, PM10 and NO2 can contribute to a worst Covid-19 course also among MS patients. Since a link between air pollutants, including PM2.5, PM10, NO2, and MS was already found (Bergamaschi et al., 2021; Tateo et al., 2020; Heydarpour et al., 2014; Gregory et al., 2008; Parolisi et al., 2019; Noorimotlagh et al., 2021; Bergamaschi et al., 2018; Corsete et al., 2020; Heydarpour et al., 2014; Gregory et al., 2008; Parolisi et al., 2021; Jeanjean et al., 2018), it was reasonable to expect that the effects of pollution, widely documented in the general population, would have been confirmed or even further enhanced among MS patients and thus our results are not surprising. Among MS patients, air pollution can thus additionally contribute to the risk of unfavorable Covid-19 course, being a co-factor together with other well known risk factors for the general population (older age, higher BMI and presence of comorbidities) and for patients with MS (higher EDSS, progressive MS phenotype, disease duration and Anti-CD20 treatment).

Concerning immunological and pro-inflammatory mechanisms that could aggravate Covid-19, it is hypothesized that the hasty aggression in course of respiratory illness is fostered by the massive release of pro-inflammatory cytokines, followed by lung inflammation (World Health Organization 2020). Therefore, the exposure to atmospheric pollution could induce modifications of the immune system (Tsai et al., 2019) favoring an auto-aggressive response in a typically inflammatory autoimmune disease such as multiple sclerosis. A severe evolution of Covid-19 in MS might be led by the cytokine storm syndrome, characterized by the increase of IL-2, IL-7, granulocyte- colony stimulating factor (GCSF) and interferon (IFN) (Koshy et al., 2012; van der Meide et al., 2016; Zeyneloglu et al., 2016). The cytokine response is followed by an increase in IL-6 and IL-8, which further enhance the inflammatory process and accelerate the symptoms (Tsai et al., 2019). Therefore, increased levels of these cytokines in MS patients could lead to a more severe Covid-19, as suggested by the higher EDSS (2.41 vs 2.22, p<0.01) and the higher proportion of progressive MS (19.6% vs 14.3%, p<0.01).
factor, interferon-γ-inducible protein 10, monocyte chemo-attractant protein 1, macrophage inflammatory protein 1-α, and tumor necrosis factor-α) (Huang et al., 2020). In addition, the oxidative stress induced by PM2.5 in the lungs, resulting in cell damage, local/systemic inflammation and cytokine release, (Veldhoen et al., 2022) might enhance the inflammatory framework in Covid-19. As a counter-proof of this argument, we have the findings on effectiveness of therapeutic strategies based selective cytokine blockade (e.g., Tocilizumab) (Abidi et al., 2022).

A relevant strength of this study consists in the evaluation of the complex nature of pollutants as an environmental mixture, using WQS and Lasso approaches to take into account the high observed correlations between pollutants and to infer the overall mixture effect while assessing the specific contribution of each pollutant to the mixture (Dominici et al., 2010). Even if focusing on single exposures as if exposure occurs individually may lead to inadequate and misleading conclusions, this is what is most commonly done in practice (Braun et al., 2016) and in fact current studies on environmental factors and Covid-19 have generally focused on evaluating pollutants one at a time. An overall harmful effect of the pollutants was confirmed when accounting for the high correlation, and we consistently identified NO2 and PM2.5 as the main contributors of the mixture to Covid-19 pneumonia, thus leaving to PM10 a minor role in this association. The fact that PM2.5 is selected instead of PM10 is not surprising. PM2.5 is in fact more toxic than bigger particles since it is easily respirable and can deposit more deeply in the lungs than larger particles, irritate and corrode the alveolar wall, and thus affect lung function (Ciencewicki and Jaspers, 2007; Xing et al., 2016). Concerning limitations of this study, even if looking at the three pollutants simultaneously is a strength of this work, a future research evaluating other additional pollutants within the environmental mixture will guarantee a more complete overview. Another limitation of this study regards the exposure assessment. Specifically, some people with MS are quite active and thus it is not unlikely the long-distance commuting for work reasons. Even if the specification of the meaning of active time (exclusion of sleeping hours) may help the patients in deciding where they spend most of the active time, they may still find it difficult to consider whether they spend more time at home or at their job place. In this situation of indecision, patients could report only one place of exposure and thus a source of bias was introduced. In future studies, giving the opportunity to provide two places of exposure in case of indecision would surely result in a more complete and accurate view of the patient’s profile. Finally, another limitation of this work consists in the unavailability of variables on the socioeconomic status, that may act as possible confounders.

In conclusion, even if several other factors may explain the unfavorable course of Covid-19 infection, also air pollution plays its role and since it is a modifiable exposure, urgent measures should be adopted especially to protect the most vulnerable population.

Funding statement

No funding to declare.

CRediT authorship contribution statement

Marta Ponzano: Conceptualization, Methodology, Formal analysis, Writing - Original Draft; Irene Schiavetti: Conceptualization, Formal analysis, Writing - Review & Editing; Roberto Bergamaschi: Conceptualization, Writing - Review & Editing; Enrico Pisoni: Conceptualization, Methodology, Writing - Review & Editing; Andrea Bellavia: Conceptualization, Methodology, Writing - Review & Editing; Giulia Mallucci: Conceptualization, Writing - Review & Editing; Luca Carmisciano: Writing - Review & Editing, Data Curation; Cinzia Cordioli: Writing - Review & Editing, Data Curation; Girolama Alessandra Marfia: Writing - Review & Editing, Data Curation; Eleonora Cocco: Writing - Review & Editing,
Serono, Teva and Roche. P. Immovilli reports personal fees from Roche, personal fees from Biogen, personal fees from Merck, outside the submitted work. V. Brescia Morra has received funding for travel, speaker honoraria, advisory board and research support from Merck Serono, Novartis, Biogen Idec, TEVA, Genzyme, Roche, Bayer, Almirall. G. Comi reports personal fees from Novartis, Teva Pharmaceutical Industries Ltd, Teva Italia Srl, Sanofi Genzyme, Genzyme Corporation, Genzyme Europe, Merck KGaA, Merck Serono SpA, Celgene Group, Biogen Idec, Biogen Italia Srl, F. Hoffman-La Roche, Roche SpA, Almirall SpA, Forward Pharma, Medday, Excemed, outside the submitted work. F. Patti reports grants from Biogen, grants from Merck, grants from FISM, grants from Onlus association, grants from University of Catania, personal fees from Almirall, personal fees from Bayer, personal fees from Biogen, personal fees from Merck, personal fees from Roche, personal fees from Sanofi, personal fees from TEVA, outside the submitted work.

Acknowledgments

The air quality data used here rely on products made available in open access by the CAMS Policy Service, at policy.atmosphere.copernicus.eu.

Supplementary materials

Supplementary material associated with this article can be found, in the online version, at doi:10.1016/j.msard.2022.104243.

References

Aghaleh, E., El-Nakey, W.S., Alifeh, E., Rahman, N., Petrosian, G.A., El-Lahabi, R., 2022. Maltell Tocilizumab and COVID-19: timing of Administration and Efficacy. J. Front Pharmacol. 13, 825749. https://doi.org/10.3389/fphar.2022.825749.
Bergamaschi, R., Cortese, A., Pichiecchio, A., Berzoldi, F.G., Borrelli, P., Mallucci, G., Rovaris, M., Romani, A., Nosari, G., Villa, S., Montomoli, C., 2018. Air pollution is associated to the multiple sclerosis inflammatory activity as measured by brain MRI. Mult. Scler. 24 (12), 1578–1584. https://doi.org/10.1177/1352458517772686. Epub 2017 Aug 14. PMID: 28805546.
Bergamaschi, R., Moni, M.C., Trivilli, L., Mallucci, G., Gerosa, L., Pisoni, E., Montomoli, C., 2021. PM2.5 exposure as a risk factor for multiple sclerosis. An ecological study with a Bayesian mapping approach. Environ. Sci. Pollut. Res. Int. 28 (3), 2804–2809. https://doi.org/10.1007/s11356-020-10595-3. Epub 2020 Sep 7. PMID: 32894443; PMCID: PMC7788018.
Bergamaschi, R., Ponzonzo, M., Schiavetti, L., Carmicciniano, L., Cordioli, C., Filippi, M., Radaelli, M., Immovilli, P., Capobianco, M., Di Rossi, N., Bricchetto, G., Cocco, E., Scandellari, C., Cavalla, P., Pesci, I., Zito, A., Confalonieri, P., Martina, G.A., Perini, P., Ingles, M., Troiano, M., V. Brescia Morra, Pieni, E., Tedeschi, G., Comi, G., Battaglia, M.A., Patti, F., Salvetti, M., MP, Sormani, 2022. MSx-19 study group. The effect of air pollution on COVID-19 severity in a sample of patients with multiple sclerosis. Eur. J. Neurol. 29 (2), 535–542. https://doi.org/10.1111/ene.15107. Epub 2021 Nov 15. PMID: 34735549; PMCID: PMC8527772.
Bourdrel, T., Annesi-Maesano, I., Alahmad, B., Maesano, C.N., Bind, M.A., 2021. The impact of outdoor air pollution on COVID-19: a review of evidence from in vitro, animal, and human studies. Eur. Resp. Rev. 30 (159), 200242 https://doi.org/10.1183/09059181.2020.2020. PMID: 33566525; PMCID: PMC7879466.
Braun, J.M., Gennings, C., Hauser, R., Webster, T.F. What Can Epidemiological Studies Tell Us about the Impact of Chemical Mixtures on Human Health? Environ Health Perspect. 2016 Jan;124(1):A6–8. doi: 10.1289/ehp.1510569. PMID: 26720830; PMCID: PMC4710611.
Carrico, C., Gennings, C., Wheeler, D.C., 2015. Factor-Litvak P. Characterization of weighted quantile sum regression for highly correlated data in a risk analysis setting. J. Agricult. Biol. Environ. Stat. 20 (1), 100–120.
Cenewicke, J., Jaspers, I., 2007. Air pollution and respiratory viral infection. Inhal. Toxicol. 19 (14), 1135–1146. https://doi.org/10.1080/09958700701655434.
Cortese, A., Lova, I., Comoli, P., Volpe, E., Villa, S., Mallucci, G., La Salvia, S., Romani, A., Franciotta, D., Bollati, V., Basso, S., Guido, I., Quartuccio, G., Battistini, L., Cereda, C., Bergamaschi, R. 2020. Air pollution as a contributor to the inflammatory activity of multiple sclerosis. J. Neuroinflammation 17 (1), 334.
Czarzota, J., Gennings, C., Wheeler, D.C. Assessment of weighted quantile sum regression for modeling chemical mixtures and cancer risk. Cancer Inf. 2015 Jan;14: CIN-S17295.
Dominici, F., Peng, R.D., Barr, C.D., Bell, M.L., 2010. Protecting human health from air pollution: shifting from a single-pollutant to a multispot pollutant approach. Epidemiology 21 (2), 187–194. https://doi.org/10.1097/EDE.0b013e3181b82f86; PMID: 20610561; PMCID: PMCP4378702.
Gregory 2nd, A.C., Sheddell, D.G., Okonuk, I.S., Gieseker, K.E. 2008. Multiple Sclerosis disease distribution and potential impact of environmental air pollutants in Georgia. Sci. Total Environ. 396 (1), 42–51.

Declaration of Competing Interest

Sormani MP received consulting fees from Roche, Biogen, Merck, Novartis, Sanofi, Celgene, Immucin, Genecuro, GSK, Medday; received payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing or educational events from Roche, Biogen Merck, Novartis, Sanofi, Celgene; participated in a Data Safety Monitoring Board or Advisory Board for Roche, Novartis, Merck. Caleri F received honoraria for lectures or presentation from Biogen, Merck, Teva, Novartis, Sanofi-Genzyne, Roche; received support for attending meeting and travel grant from Biogen, Merck, Teva, Novartis, Sanofi-Genzyne, Roche; received honoraria for participation on Advisory Boards from Biogen, Merck, Teva, Novartis, Sanofi-Genzyne, Roche. Cordioli C received grants or contracts from Roche, Novartis, Merck Serono, Biogen, Celgene; received consulting fees from Biogen. Inglese M received grants or contracts from FISM, INAIL, European Union. Salvetti M received grants or contracts from Biogen, Merck, Novartis; received payments or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing or educational events from Biogen, Merck, Novartis, Roche, Sanofi. R. Bergamaschi has served on scientific advisory boards for Biogen, Merck-Serono, Novartis, Sanofi-Genzyne; received research support from Almirall, Bayer, Biogen, Merck-Serono, Novartis, Sanofi-Genzyne; received support for travel and congress from Biogen, Roche, Merck-Serono, Sanofi-Genzyne, Teva; received honoraria for speaking engagements from Biogen, Merck-Serono, Novartis, Sanofi-Genzyne. M. Filippi is Editor-in-Chief of the Journal of Neurology, Associate Editor of Human Brain Mapping, Associate Editor of Radiology and Associate Editor of Neurological Sciences; received compensation for consulting services and/or speaking activities from Alexion, Almirall, Bayer, Biogen, Celgene, Eli Lilly, Genzyme, Merck-Serono, Novartis, Roche, Sanofi, Takeda and Teva Pharmaceutical Industries; and receives research support from Biogen Idec, Merck-Serono, Novartis, Roche, Teva Pharmaceutical Industries, Italian Ministry of Health, Fondazione Italiana Sclerosi Multipla and ARISLA (Fondazione Italiana di Ricerca per la SLM). He received speaker honoraria from the following companies: Biogen, Merck, Novartis, Roche, Sanofi-Genzyne and TEVA. M. Radaelli received speaker honoraria from Biogen Idec, Sanofi-Genzyne, Novartis and Merck Serono and funding for travel to scientific meetings from Biogen Idec, Sanofi-Genzyne, Novartis, Merck
